All consecutive patients admitted in ILBS from MAY 2015 to DECEMBER 2016.ACLF (Acute on chronic Liver Failure). ACLF will be randomize into Group 1: MVP (Modest Volume Paracentesis) OF Less than 5 liters with IV albumin at a dose 8 gms/L of ascitic fluid Group 2: MVP (Modest Volume Paracentesis) of Less than 5 liters without albumin
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
Intravenous albumin 8 gms/L of ascitic fluid
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Total number of patients develop Circulatory Dysfunction because of paracentesis.
Time frame: 1 Year
Survival
Time frame: 28 days
Total number of patients develop hepatorenal Syndrome.
Time frame: 1 Year
Total number of patients develop hyponatremia.
Time frame: 1 Year
Changes in aldosterone with volume of ascitic fluid tap
Time frame: 1 Year
Changes in plasma renin activity
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.